Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.

[1]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[2]  K. Cowan,et al.  Antineoplastic Drug Resistance and Breast Cancer , 1993, Annals of the New York Academy of Sciences.

[3]  H. Magdelenat,et al.  Prognostic Value of the S‐Phase Fraction of Breast Cancers Treated by Primary Radiotherapy or Neoadjuvant Chemotherapy , 1993, Annals of the New York Academy of Sciences.

[4]  R. Arceci.  Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments] , 1993 .

[5]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[6]  D. Schaid,et al.  DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. McGuire,et al.  Prognosis and treatment decisions in patients with breast cancer without axillary node involvement , 1992, Cancer.

[8]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Frierson.  Ploidy Analysis and S‐Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomas of the Breast , 1991, The American journal of surgical pathology.

[11]  L. Case,et al.  The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients , 1990, Cancer.

[12]  J. Schneider,et al.  P-glycoprotein expression in treated and untreated human breast cancer. , 1989, British Journal of Cancer.

[13]  H. Magdelenat,et al.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. , 1989, Journal of the National Cancer Institute.

[14]  S. Ménard,et al.  Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients , 1988, Cancer.

[15]  A. Zajdela,et al.  DNA flow cytometry applied to fine needle sampling of human breast cancer , 1988, Cancer.

[16]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  B. Asselain,et al.  Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.